Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in ... - Ipsen
Cabometyx (cabozantinib) showed significant reduction in disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, according to final data from the CABINET Phase III trial. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency. The data were presented at ESMO 2024 and published in the New England Journal of Medicine.
Reference News
Cabometyx (cabozantinib) showed significant reduction in disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, according to final data from the CABINET Phase III trial. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency. The data were presented at ESMO 2024 and published in the New England Journal of Medicine.